Literature DB >> 8283165

A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation.

A Ruffatti1, G De Silvestro, A Ghirardello, A Calligaro, T Del Ross, G Thiene, S Todesco.   

Abstract

We report the clinical observation of a 23-year-old woman affected by the so-called 'catastrophic antiphospholipid syndrome'. Within a 3-month period she suffered a number of thrombotic events and haemolytic anaemia with thrombocytopenia and had high levels of immunoglobulins G and M and anticardiolipin antibodies associated with lupus anticoagulant activity. The severity of the clinical and laboratory changes is described and diagnostic and therapeutic difficulties are discussed. The apparent control of thrombotic events only with high levels of warfarin anticoagulation is stressed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8283165     DOI: 10.1111/j.1365-2796.1994.tb01036.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  4 in total

1.  Correction for age of anticardiolipin antibodies cut-off points.

Authors:  E Rapizzi; A Ruffatti; M Tonello; A Piccoli; A Calligaro; P Sfriso; S Todesco
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  Trends in immunoglobulin G anticardiolipin antibodies in ten successful heparin-treated pregnancies.

Authors:  A Ruffatti; M P Scapinello; S Tonetto; L Di Lenardo; A Piccoli; P Grella; S Todesco
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  Anticardiolipin antibodies and antiphospholipid syndrome in chronic discoid lupus erythematosus.

Authors:  A Ruffatti; C Veller-Fornasa; G M Patrassi; E Sartori; M Tonello; S Tonetto; A Peserico; S Todesco
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

4.  Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome.

Authors:  V Pengo; A Biasiolo; M Grazia Fior; A Ruffatti
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.